Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial

Circulation. 2001 Jun 19;103(24):2928-34. doi: 10.1161/01.cir.103.24.2928.

Abstract

Background: PTCA of a coronary stenosis without documented ischemia at noninvasive stress testing is often performed, but its benefit is unproven. Coronary pressure-derived fractional flow reserve (FFR) is an invasive index of stenosis severity that is a reliable substitute for noninvasive stress testing. A value of 0.75 identifies stenoses with hemodynamic significance.

Methods and results: In 325 patients for whom PTCA was planned and who did not have documented ischemia, FFR of the stenosis was measured. If FFR was >0.75, patients were randomly assigned to deferral (deferral group; n=91) or performance (performance group; n=90) of PTCA. If FFR was <0.75, PTCA was performed as planned (reference group; n=144). Clinical follow-up was obtained at 1, 3, 6, 12, and 24 months. Event-free survival was similar between the deferral and performance groups (92% versus 89% at 12 months and 89% versus 83% at 24 months) but was significantly lower in the reference group (80% at 12 months and 78% at 24 months). In addition, the percentage of patients free from angina was similar between the deferral and performance groups (49% versus 50% at 12 months and 70% versus 51% at 24 months) but was significantly higher in the reference group (67% at 12 and 80% at 24 months).

Conclusions: In patients with a coronary stenosis without evidence of ischemia, coronary pressure-derived FFR identifies those who will benefit from PTCA.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Angina Pectoris / prevention & control
  • Angioplasty, Balloon, Coronary* / adverse effects
  • Blood Flow Velocity
  • Blood Pressure
  • Coronary Angiography
  • Coronary Circulation*
  • Coronary Disease / diagnosis*
  • Coronary Disease / physiopathology*
  • Coronary Disease / therapy
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Male
  • Middle Aged
  • Patient Selection
  • Predictive Value of Tests
  • Severity of Illness Index*
  • Treatment Outcome

Substances

  • Hypolipidemic Agents